RU2019119584A3 - - Google Patents

Download PDF

Info

Publication number
RU2019119584A3
RU2019119584A3 RU2019119584A RU2019119584A RU2019119584A3 RU 2019119584 A3 RU2019119584 A3 RU 2019119584A3 RU 2019119584 A RU2019119584 A RU 2019119584A RU 2019119584 A RU2019119584 A RU 2019119584A RU 2019119584 A3 RU2019119584 A3 RU 2019119584A3
Authority
RU
Russia
Application number
RU2019119584A
Other languages
Russian (ru)
Other versions
RU2019119584A (ru
RU2752384C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019119584A publication Critical patent/RU2019119584A/ru
Publication of RU2019119584A3 publication Critical patent/RU2019119584A3/ru
Application granted granted Critical
Publication of RU2752384C2 publication Critical patent/RU2752384C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2019119584A 2016-11-25 2017-11-24 Способ получения триазолопиридинового соединения RU2752384C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-228897 2016-11-25
JP2016228897 2016-11-25
PCT/JP2017/042239 WO2018097254A1 (ja) 2016-11-25 2017-11-24 トリアゾロピリジン化合物の製造方法

Publications (3)

Publication Number Publication Date
RU2019119584A RU2019119584A (ru) 2020-12-25
RU2019119584A3 true RU2019119584A3 (enExample) 2021-03-25
RU2752384C2 RU2752384C2 (ru) 2021-07-26

Family

ID=62195187

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019119584A RU2752384C2 (ru) 2016-11-25 2017-11-24 Способ получения триазолопиридинового соединения

Country Status (11)

Country Link
US (1) US11434238B2 (enExample)
EP (1) EP3546459A4 (enExample)
JP (2) JP6600103B2 (enExample)
KR (1) KR102523786B1 (enExample)
CN (1) CN110214139B (enExample)
AU (1) AU2017364725B2 (enExample)
CA (1) CA3044654A1 (enExample)
IL (1) IL266858B (enExample)
MX (1) MX2019006083A (enExample)
RU (1) RU2752384C2 (enExample)
WO (1) WO2018097254A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017364725B2 (en) * 2016-11-25 2021-04-01 Japan Tobacco Inc. Method for producing triazolopyridine compound
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
CN114773333A (zh) * 2021-12-25 2022-07-22 上海泰坦科技股份有限公司 一种卤代三唑并吡啶的合成方法
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
CN119039291A (zh) * 2024-09-09 2024-11-29 南京药坦生物科技有限公司 一种恩那度司他中间体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
JP6814134B2 (ja) 2015-05-28 2021-01-13 日本たばこ産業株式会社 糖尿病性腎症を治療又は予防する方法
EP3374350B1 (en) * 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
AU2017364725B2 (en) * 2016-11-25 2021-04-01 Japan Tobacco Inc. Method for producing triazolopyridine compound

Also Published As

Publication number Publication date
EP3546459A4 (en) 2020-05-20
RU2019119584A (ru) 2020-12-25
US11434238B2 (en) 2022-09-06
RU2752384C2 (ru) 2021-07-26
IL266858A (en) 2019-08-29
US20200339563A1 (en) 2020-10-29
JPWO2018097254A1 (ja) 2019-10-17
CN110214139B (zh) 2022-08-23
KR20190085004A (ko) 2019-07-17
JP2020073474A (ja) 2020-05-14
WO2018097254A1 (ja) 2018-05-31
CN110214139A (zh) 2019-09-06
KR102523786B1 (ko) 2023-04-20
IL266858B (en) 2021-10-31
AU2017364725B2 (en) 2021-04-01
MX2019006083A (es) 2019-07-10
EP3546459A1 (en) 2019-10-02
AU2017364725A1 (en) 2019-06-13
JP6600103B2 (ja) 2019-10-30
CA3044654A1 (en) 2018-05-31
BR112019010017A2 (pt) 2019-08-20

Similar Documents

Publication Publication Date Title
CH714036A1 (enExample)
BR122021026889A2 (enExample)
BR112019009201A2 (enExample)
BR112019008128A2 (enExample)
BR112018004348A2 (enExample)
BR112019000781A2 (enExample)
BR112019009262A2 (enExample)
BR112019008107A2 (enExample)
BR202016030146U2 (enExample)
BR102016018018A2 (enExample)
CN303536629S (enExample)
CN303537730S (enExample)
CN303536110S (enExample)
CN303536210S (enExample)
CN303536212S (enExample)
CN303536215S (enExample)
CN303536233S (enExample)
CN303548870S (enExample)
CN303536360S (enExample)
CN303536391S (enExample)
CN303536482S (enExample)
CN303536548S (enExample)
CN303536550S (enExample)
CN303536579S (enExample)
CN303535619S (enExample)